Compare Neurocrine Biosciences Inc (NBIX) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs AT&T Inc. — how do they compare? Neurocrine Biosciences Inc trades at $158.62 (market cap $16.46B), while AT&T Inc. trades at $24.44 (market cap $167.88B). The key difference: AT&T Inc. is far larger — about 10.2× Neurocrine Biosciences Inc's market cap, and AT&T Inc. pays a 4.53% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | T | |
|---|---|---|
Market Cap | $16.46B | $167.88B |
Sector | Health | Media |
52-Week High | $185.50 | $29.62 |
52-Week Low | $123.10 | $20.49 |
Enterprise Value | $16.48B | $313.20B |
Dividend Yield | — | 4.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.
AT&T (T) trades at $24.08, up 1.18% with a bullish technical signal and strong fundamentals. The stock shows consistent earnings beats, with Q2 2026 EPS of $0.65 exceeding expectations. Valuation remains attractive with a P/E of 8.1 and dividend yield of 4.7%. Recent developments include fiber expansion and AI initiatives, while cash flow improved to $15.1B in 2025. Technical indicators show bullish moving averages with resistance near $24-25.
Outlook remains positive with 15% upside to consensus price target of $27.69. Investment appeal includes strong cash flow generation, dividend sustainability, and ongoing network investments. Key risks include competitive pressure from SpaceX's wireless ambitions and execution challenges in fiber deployment. Analyst consensus leans bullish with 41% buy ratings versus 10% sell recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
